
Tamara Mihic
Doctor of Philosophy in Pharmaceutical Sciences (PhD)
Opioid Agonist Treatment Initiation and Continuation in a Hospital Setting
If you are passionate about health sciences research that makes a difference in people's lives, you're in good hands. We offer award-wining graduate programs led by world-class researchers. You'll have access to top-tier facilities and be working alongside the best and brightest in the field, conducting research that addresses real life problems. Our paradigm-changing approach is collaborative, innovative, and results-driven.
We're tackling diseases like asthma / chronic obstructive pulmonary disease, diabetes, cancer, heart disease, and arthritis. We're developing better ways to deliver drugs and prevent adverse drug reactions. And we're conducting clinical and economic research in pharmaceutical outcomes.
Our reputation as a top research centre attracts some of the brightest and most productive minds in the field. Our faculty includes Canada Research Chairs, Michael Smith Foundation for Health Research Scholars and Senior Scholars, and Distinguished University Scholars.
We are innovators in pharmacy education, research and practice, with the goal of supporting the optimization of drug therapy in the pursuit of improved patient outcomes.
adMare BioInnovations is located in our building. It is an independent, non-profit organization with a focus on bridging the gap between academic discoveries in the health sciences and the development of new medicines to treat human disease. The Faculty partners with adMare BioInnovations to provide unique research and mentoring opportunities for MSc and PhD students.
We are also home to several sophisticated research centres that specialize in the areas of human genome and exome sequencing, and health outcomes research.
Opened in 2012, the Pharmaceutical Sciences Building at UBC is a state-of-the-art learning and research facility. The building houses modern, modular labs designed specifically for the type of research intended for the space. Our classroom facilities are fitted with advanced technology to facilitate new modes of learning.
Measuring 246,000 square feet, it's an eye-catching addition to our campus, and has drawn attention and admiration from around the world—including 15 awards of excellence.
As a leading research faculty, we conduct ground-breaking research in the pharmaceutical sciences – all with the goal of addressing the pressing health needs of society and improving lives. Our research activities centre around four areas of focus.
This theme covers our activities in epidemiological analysis, health outcomes and health economics research seeking solutions for the predictive enhancement of intervention strategies for practical and preventive healthcare. The impact of this work is used to shape policy to optimize the allocation of health care resources as well as defining the efficacy of healthcare interventions and strategy.
This highly interdisciplinary theme embodies research directed at the interactions of therapeutic agents with human cells, and covers fundamental questions of the mechanisms of the drug action through to the behaviour of drugs in human systems. These studies are used to inform and optimize the development and delivery of drug intervention regimes for clinical practice and the pharmaceutical industry.
This theme applies our expertise in the chemical biology of the fabrication and handling of nanoscopic materials to drug discovery and delivery. Sensing and screening technologies are also an important focus.
Our research in this theme addresses the issue of scholarship in pharmacy and the pharmaceutical sciences with a view to augment our educational research capacity and enhance the methodologies of teaching practice, student learning and curriculum decision-making.
Name | Research Interests |
---|---|
Cairns, Brian | Neurosciences, biological and chemical aspects; Neurosciences, medical and physiological and health aspects; Pharmacology and pharmaceutical sciences (except clinical aspects); electrophysiology; headache; Neuropharmacology; Oro-Facial Pain; pain; pain mechanisms; peripheral analgesics; sex-related differences; temporomandibular disorders |
Chang, Thomas | Pharmacology and pharmaceutical sciences (except clinical aspects) |
Cheng, Miffy | nanomedicine; gene therapy to combat chronic diseases |
Conklin, Annalijn | Public health nutrition policy; Other basic medicine and life sciences; Social Determinants of Dietary and Metabolic Disorders; social nutritional epidemiology; women's health; Health Equity; Chronic Diseases in Elderly; Obesity; CVD risk factors; healthy ageing; food and nutrition policy; Indigenous health; Community Health / Public Health; disease management evaluation; healthcare quality improvement |
Coughtrie, Michael | Drug metabolizing enzymes |
Cragg, Jacquelyn | Epidemiology (except nutritional and veterinary epidemiology); data science; open science; Causal inference; Drug Effectiveness; Drug Safety; Epidemiology; neuro-epidemiology; Neurological diseases; Spinal cord injury; Amyotrophic Lateral Sclerosis (ALS); multiple sclerosis; Parkinson’s disease |
De Vera, Mary | examining how eHealth technologies can support new and existing models of care to improve care delivery and patient outcomes; exploring patients' perspectives and experiences with medication taking and adherence; and evaluating the use and impacts of medications among pregnant women, particularly with inflammatory conditions. |
Finbloom, Joel | Drug discovery, design and delivery; Biologically active molecules; Nanochemistry; Antimicrobial resistance; Nanomedicine; nanomedicine; Chemical Biology; drug delivery; Pharmaceutical Sciences; Infectious disease; Bacterial Biofilms; Microbiome; Probiotics; Antibiotic resistance |
Frankel, Adam | Other basic medicine and life sciences; Enzymes (including kinetics and mechanisms, and biocatalyst); Protein Biochemistry; arginine methylation; Histones; Nucleosomes; post-translational modifications; Biological and Biochemical Mechanisms; Organic Molecules and Biomolecules; Bioactive Molecules; Proteins; Chemical Biology; drug discovery; Target Engagement; yeast; Amino acids |
Giaever, Guri | Model organisms, human therapeutics, high-throughput cell biology, drug synergy, technologies for understanding relationship between chromatic structure and transcriptional regulation |
Harrison, Mark | measurement and valuation of health, health technology and policy assessment, and preferences for healthcare interventions; evaluation/re-evaluation of the type of health care that is provided, the point in the treatment pathway, and the way in which it is delivered |
Jarvis-Selinger, Sandra | Education, human learning, development, and instruction, education innovation, konwledge translation, teaching excellence, curriculum design, technology |
Johnson, Kate | Health care effectiveness and outcomes; Health economics; Health outcomes; Epidemiology |
Krentz, Nicole | Human development and organogenesis; Pharmacology and pharmaceutical sciences, n.e.c.; Human physiology, n.e.c.; Diabetes; Developmental biology; Genetics |
Kumar, Ujendra | Somatostatin hormone, molecular pharmacology, Somatostatin, , Hormones, somatostatin, locomotor and cognitive function, neurodegenerative diseases, drugs |
Lalji, Fawziah | Epidemiology (except nutritional and veterinary epidemiology); Pharmacoepidemiology; Infectious diseases; Immunization; Antibiotics and Resistance; Vaccine preventable diseases |
Li, Shyh-Dar | Drug discovery, design and delivery; Nano-technology; biopharmaceutics; drug delivery; nanomedicine; pharmaceutics; Gene delivery and therapy |
Loewen, Peter | Cardiology and circulatory sciences (including cardiovascular disease); Clinical pharmacy and pharmacy practice; Knowledge translation and implementation science in health; Population health interventions; atrial fibrillation; Pharmacoepidemiology; Thrombosis and Embolism; adherence to medication; Cardiovascular diseases; Arrhythmia; Heart Failure; stroke; Health Care Technologies; Professional Practices; Hematology; decision making; clinical prediction rules; hospital pharmacy practice; knowledge translation of evidence to patient care; patient complexiometry; patient decision aids; patient education; pharmacy practice; prediction of stroke and bleeding in atrial fibrillation patients; quality of care, quality drug therapy; Shared decision-making; stroke prevention therapy; use of mobile technology for clinical decision-making |
Lynd, Larry | health economics, orphan drugs, pharmaceutical policy, respiratory medicine, epidemiology, pharmacoepidemiology, rare diseases |
Maharaj, Anil | Pharmacology and pharmaceutical sciences, n.e.c.; Pharmacometrics; Pharmacokinetics/Pharmacodynamics; Obstetric and Pediatric Pharmacology |
McCormack, James | Knowledge translation and evidence-based practice |
Nislow, Corey | Genomics; Mechanisms of carcinogenesis; genomics; Genetics; drug discovery; Biotechnology; Space Biology |
Page, Brent | Drug discovery, design and delivery; Cell Signaling and Cancer; Cancer; Cell signaling; Chemical Biology; Drug development; Drug Discovery, Design and Delivery; Medicinal Chemistry; Target Engagement |
Rodrigues, Brian | Pharmacology and pharmaceutical sciences (except clinical aspects); Diabetes; Cardiomyopathy; Heart Failure; Energy Metabolism; Cardiovascular metabolism; Endothelial cell - cardiomyocyte crosstalk; Vascular Endothelial Growth factors |
Ross, Colin | Care; Genomics; Neurosciences, biological and chemical aspects; Neurosciences, medical and physiological and health aspects; Pharmacology and pharmaceutical sciences (except clinical aspects); Biomedical Technologies; Drug Metabolism; Gene Therapy; Gene-based therapeutics; Pharmacogenomics; Precision Medicine; transgenic models |
This is an incomplete sample of recent publications in chronological order by UBC faculty members with a primary appointment in the Faculty of Pharmaceutical Sciences.
Year | Citation | Program |
---|---|---|
2025 | In Dr. Oveisi's research, a multi-method approach was used to examine cancer’s impact on adolescent and young adult sexual and reproductive health. Quantitative analysis showed higher risks of early menopause, painful sex, and infertility. Qualitatively, patients discussed impacts on personal, relationship, and community levels, and barriers to receiving appropriate care. | Doctor of Philosophy in Pharmaceutical Sciences (PhD) |
2025 | Dr. Thiombane used chemogenomic CRISPR screens to study a class of widely used cancer chemotherapeutic drugs named anthracyclines. Her research provided a global view of all the drug-gene interactions for several clinically used anthracyclines. Her data supports the renewed interest in the clinical use of aclarubicin for cancer chemotherapy. | Doctor of Philosophy in Pharmaceutical Sciences (PhD) |
2024 | Dr. Rowley studied protein arginine N-methyltransferase 2 (PRMT2), an enzyme found to be dysregulated in disease. He developed new techniques to study PRMT2 and how it interacts with other proteins. Findings from his research suggest that PRMT2 orchestrates the activities of other methyltransferases. | Doctor of Philosophy in Pharmaceutical Sciences (PhD) |
2024 | Dr. Lee explored heparanase’s role in providing heart energy and its changes in diabetes. He also found that heparanase overexpression led to development of physiological cardiac hypertrophy, however, its actions are negated during diabetes, resulting in heart failure. Further investigation may enhance the management of diabetic heart disease. | Doctor of Philosophy in Pharmaceutical Sciences (PhD) |
2024 | Dr. Rebić used nationally representative data to generate policy-relevant information on the Canadian burden of medication non-adherence, individual and healthcare system factors increasing the risk for ineffective care, and the impact of sex and gender-related inequities. Her thesis provides real-world evidence for universal Pharmacare in Canada. | Doctor of Philosophy in Pharmaceutical Sciences (PhD) |
2024 | Dr. Tafech's research focused on advancing gene therapies for cystic fibrosis, the most common fatal genetic disorder affecting Canadian children and young adults. His work identified nano-based strategies that significantly enhanced CRISPR-mRNA delivery and gene editing in CF, driving promising progress in this disease and other genetic disorders. | Doctor of Philosophy in Pharmaceutical Sciences (PhD) |
2024 | Dr. Iliev's work focused on the development of new cancer therapies. It included the design, synthesis and testing of experimental inhibitors, pushing the boundaries of traditional medicinal chemistry approaches. His top bioactive compounds will proceed to more advanced testing towards becoming next-generation cancer therapeutics. | Doctor of Philosophy in Pharmaceutical Sciences (PhD) |
2024 | Dr. Lee developed a decision-analytic model for evaluating long-term benefits of early interventions for asthma at the population level. He generated key evidence on the disease course of asthma and demonstrated the utility of this model by showing far-reaching benefits of reducing unnecessary infant antibiotic exposure on the burden of asthma. | Doctor of Philosophy in Pharmaceutical Sciences (PhD) |
2024 | Dr. Vo examined racial disparity in health outcomes and healthcare participation. He found that racialized individuals experience inadequate pain management, and are less likely to participate in health research due to distrust. These findings highlight the impact of structural racism on healthcare access and stress the urgent need for systemic changes to achieve health equity. | Doctor of Philosophy in Pharmaceutical Sciences (PhD) |
2024 | Dr. Soukhtehzari studied glycobiology of breast cancer and identified two novel polysialylated proteins that contributed in breast cancer progression and studied their function and roles in metastasis and breast cancer patients prognosis. | Doctor of Philosophy in Pharmaceutical Sciences (PhD) |